NEWS

Bukwang Pharmaceutical increased the number of patients for the clinical trial of...

[April 13, 2021]

Bukwang announced that they decided to increase the patients of the second domestic clinical trial(CLV-203) of covid-19(SARS-CoV-2) treatment because they found the tendency of viruses’ quantity reduction compared to placebo in the first domestic clinical trial(CLV-201). They explained that the analysis of CLV-201 has been still ongoing, so the final official data of it will come later. The reason why they increased the number of patients in CLV-203 which measures the quantity of  live viruses is to reinforce the reliability of the data. 40 patients which...

R&D

Bukwang Pharmaceutical increased the number of patients for the clinical trial of covid-19 treatment

[April 13, 2021]

Bukwang announced that they decided to increase the patients of the second domestic clinical trial(CLV-203) of covid-19(SARS-CoV-2) treatment...

PRODUCTS
COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...

|    ​Korean    |

7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square